Genomind: Cynthia Kilroy
Genomind, a company developing pharmacogenetic tests for mental health conditions, has appointed Cythia Kilroy as chief strategy and corporate development officer. She joins the company from Cognizant, where she held positions in the healthcare and health strategy groups. Kilroy has also previously worked for Optum, Huron Consulting Group, and her own firm, CCK Consulting.
Genomind has also appointed Stephen Saklad to its scientific advisory board. Saklad is a clinical professor of pharmacotherapy, and adjoint professor at the University of Texas School of Medicine; and director of the Psychiatric Pharmacy Program at the San Antonio State Hospital, Texas Department of State Health Services. He is an expert clinical pharmacologist with special interest in psychopharmacology, and holds a doctor of pharmacy degree from the University of Southern California.
Veracyte: Muna Bhanji
Veracyte has appointed Muna Bhanji to its board of directors. Bhanji most recently served as senior VP of global market access and policy, global human health at Merck. She has previously served on the board of Possible Health and the Foundation of Managed Care Pharmacy. Bhanji currently serves on the boards of Ardelyx, Cytokinetics, and Corus International.
Rebus Biosystems: Neil Kennedy, Scott Kothlow
Spatial omics technology firm Rebus Biosystems announced the appointments of Neil Kennedy as chief commercial officer and Scott Kothlow as chief financial officer.
Kennedy will lead commercialization of Rebus' Esper platform, including sales, marketing, product management, and customer success. Kennedy brings 25 years of commercial experience, most recently as senior VP of commercial operations at Dovetail Genomics.
Kothlow brings 30 years of financial experience in the life sciences industry. He was previously CFO at Somalogic.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.